SCHEMBL803477

SCHEMBL803477

CCN[C@@H]1CCc2ccc(C(=O)OC)cc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 12/20 0.58
CHRNB2 P17787 1/20 0.46
CHRNA4 P43681 1/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
MAOA P21397 3/20 0.45
MAOB P27338 3/20 0.45
BCHE P06276 1/20 0.45
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45
TUBA3C P0DPH7 1/20 0.45
TUBA1B P68363 1/20 0.45
TUBA4A P68366 1/20 0.45
TUBB4B P68371 1/20 0.45
TUBB3 Q13509 1/20 0.45
TUBB2A Q13885 1/20 0.45
TUBB8 Q3ZCM7 1/20 0.45
TUBA3E Q6PEY2 1/20 0.45
TUBA1A Q71U36 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27920400 1.00 ACHE (0.58) ACHECHRNB2CHRNA4MEN1MAPT
SCHEMBL876204 0.90 ACHE (0.56) ACHEMAOAMAOBBCHE
SCHEMBL785601 0.87 MEN1 (0.46) ACHECHRNB2CHRNA4MEN1MAPT
SCHEMBL785602 0.87 MEN1 (0.46) ACHECHRNB2CHRNA4MEN1MAPT
SCHEMBL784661 0.86 ACHE (0.57) ACHEMAOAMAOBBCHE
SCHEMBL484719 0.85 CHRNB2 (0.46) ACHECHRNB2CHRNA4MEN1MAPT
SCHEMBL484717 0.85 CHRNB2 (0.46) ACHECHRNB2CHRNA4MEN1MAPT
SCHEMBL484904 0.85 ACHE (0.55) ACHECHRNB2CHRNA4MEN1MAPT
SCHEMBL484905 0.85 ACHE (0.55) ACHECHRNB2CHRNA4MEN1MAPT
SCHEMBL13168329 0.83 KMT2A (0.47) ACHECHRNB2CHRNA4MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
CN-103097354-A Substituted benzamide compounds GRUENENTHAL CHEMIE 2013-05-08 CN disclosed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 ACHE 746/4885CHRNB2 636/4885CHRNA4 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.